FDA Approves Astellas' Vaprisol(R) For The Treatment Of Hypervolemic Hyponatremia

Sat, 03 Mar 2007 02:00 PM EST

... Astellas Pharma US, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vaprisol(R) (conivaptan hydrochloride injection), an arginine vasopressin (AVP) receptor antagonist, for the intravenous treatment of hypervolemic hyponatremia in hospitalized patients. [click link for full article] ...